Nafamostat Mesylate Monotherapy in Patients with Moderate COVID-19: a Single-Center, Retrospective Study
Coronavirus disease (COVID-19) has spread dramatically worldwide. Nafamostat mesylate inhibits intracellular entry of the novel severe acute respiratory syndrome coronavirus 2 and is believed to have therapeutic potential for treating patients with COVID-19. In this study, patients with moderate COV...
Gespeichert in:
| Veröffentlicht in: | Japanese Journal of Infectious Diseases 2022/09/30, Vol.75(5), pp.484-489 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 489 |
|---|---|
| container_issue | 5 |
| container_start_page | 484 |
| container_title | Japanese Journal of Infectious Diseases |
| container_volume | 75 |
| creator | Soma, Tomomi Fujii, Kentaro Yoshifuji, Ayumi Maruki, Taketomo Itoh, Kazuto Taniyama, Daisuke Kikuchi, Takahide Hasegawa, Naoki Nakamura, Morio |
| description | Coronavirus disease (COVID-19) has spread dramatically worldwide. Nafamostat mesylate inhibits intracellular entry of the novel severe acute respiratory syndrome coronavirus 2 and is believed to have therapeutic potential for treating patients with COVID-19. In this study, patients with moderate COVID-19 who were admitted to our hospital were retrospectively analyzed. Thirty-one patients received monotherapy with nafamostat mesylate, and 33 patients were treated conservatively. Nafamostat mesylate was administered with continuous intravenous infusion for an average of 4.5 days. Compared with the conservative treatment, nafamostat mesylate did not improve outcomes or laboratory data 5 days after admission. In addition, no significant differences in laboratory data 5 days after admission and outcomes in high-risk patients were observed. The incidence of hyperkalemia was significantly higher in the nafamostat mesylate group; however, none of the patients required additional treatment. In conclusion, monotherapy with nafamostat mesylate did not improve clinical outcomes in patients with moderate COVID-19. This study did not examine the therapeutic potential of combining nafamostat mesylate with other antiviral agents, and further investigation is required. Because of the high incidence of hyperkalemia, regular laboratory monitoring is required during the use of nafamostat mesylate. |
| doi_str_mv | 10.7883/yoken.JJID.2021.699 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2658644226</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2720113140</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4499-cab1e00e5e9d341edc9dd6d8b81129e3eaf5677fe7953e7be6504149869b189c3</originalsourceid><addsrcrecordid>eNpdkV1v0zAUhi3ExD7gFyAhS9xwsRR_x-YOdcA6bQwx4NZynJM1JU2K7YDy7-eupRLc2JbOc14dnwehl5TMSq3522n4Cf3s6mpxMWOE0Zky5gk6oVqLgmmunuY3F6JQnIhjdBrjihAmJSXP0DGXwlDGxAlafnaNWw8xuYRvIE6dS4Bvhn5ISwhuM-G2x19caqFPEf9p0zIX61zJ1Pz2x-KioOYddviu7e87KOYZg3COv0IKQ9yAT-1vwHdprKfn6KhxXYQX-_sMff_44dv8sri-_bSYv78uvBDGFN5VFAgBCabmgkLtTV2rWleaUmaAg2ukKssGSiM5lBUoSQQVRitTUW08P0NvdrmbMPwaISa7bqOHrnM9DGO0TEmthGBMZfT1f-hqGEOfp7OsZIRSTgXJFN9RPn8pBmjsJrRrFyZLid2KsI8i7FaE3YqwWUTuerXPHqs11Ieev5vPwGIHrPLu7-EAuJBa38E-tJRWbo9_wg-MX7pgoecP5F6fHg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2720113140</pqid></control><display><type>article</type><title>Nafamostat Mesylate Monotherapy in Patients with Moderate COVID-19: a Single-Center, Retrospective Study</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><creator>Soma, Tomomi ; Fujii, Kentaro ; Yoshifuji, Ayumi ; Maruki, Taketomo ; Itoh, Kazuto ; Taniyama, Daisuke ; Kikuchi, Takahide ; Hasegawa, Naoki ; Nakamura, Morio</creator><creatorcontrib>Soma, Tomomi ; Fujii, Kentaro ; Yoshifuji, Ayumi ; Maruki, Taketomo ; Itoh, Kazuto ; Taniyama, Daisuke ; Kikuchi, Takahide ; Hasegawa, Naoki ; Nakamura, Morio</creatorcontrib><description>Coronavirus disease (COVID-19) has spread dramatically worldwide. Nafamostat mesylate inhibits intracellular entry of the novel severe acute respiratory syndrome coronavirus 2 and is believed to have therapeutic potential for treating patients with COVID-19. In this study, patients with moderate COVID-19 who were admitted to our hospital were retrospectively analyzed. Thirty-one patients received monotherapy with nafamostat mesylate, and 33 patients were treated conservatively. Nafamostat mesylate was administered with continuous intravenous infusion for an average of 4.5 days. Compared with the conservative treatment, nafamostat mesylate did not improve outcomes or laboratory data 5 days after admission. In addition, no significant differences in laboratory data 5 days after admission and outcomes in high-risk patients were observed. The incidence of hyperkalemia was significantly higher in the nafamostat mesylate group; however, none of the patients required additional treatment. In conclusion, monotherapy with nafamostat mesylate did not improve clinical outcomes in patients with moderate COVID-19. This study did not examine the therapeutic potential of combining nafamostat mesylate with other antiviral agents, and further investigation is required. Because of the high incidence of hyperkalemia, regular laboratory monitoring is required during the use of nafamostat mesylate.</description><identifier>ISSN: 1344-6304</identifier><identifier>EISSN: 1884-2836</identifier><identifier>DOI: 10.7883/yoken.JJID.2021.699</identifier><identifier>PMID: 35491224</identifier><language>eng</language><publisher>Japan: National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee</publisher><subject>Antiviral agents ; coronavirus disease ; Coronaviruses ; COVID-19 ; Health services ; Hyperkalemia ; Intravenous administration ; Intravenous infusion ; Laboratories ; nafamostat mesylate ; Patients ; Risk groups ; SARS-CoV-2 ; Severe acute respiratory syndrome ; Severe acute respiratory syndrome coronavirus 2 ; single-center study ; Viral diseases</subject><ispartof>Japanese Journal of Infectious Diseases, 2022/09/30, Vol.75(5), pp.484-489</ispartof><rights>2022 Authors</rights><rights>Copyright Japan Science and Technology Agency 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4499-cab1e00e5e9d341edc9dd6d8b81129e3eaf5677fe7953e7be6504149869b189c3</citedby><cites>FETCH-LOGICAL-c4499-cab1e00e5e9d341edc9dd6d8b81129e3eaf5677fe7953e7be6504149869b189c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,1884,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35491224$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Soma, Tomomi</creatorcontrib><creatorcontrib>Fujii, Kentaro</creatorcontrib><creatorcontrib>Yoshifuji, Ayumi</creatorcontrib><creatorcontrib>Maruki, Taketomo</creatorcontrib><creatorcontrib>Itoh, Kazuto</creatorcontrib><creatorcontrib>Taniyama, Daisuke</creatorcontrib><creatorcontrib>Kikuchi, Takahide</creatorcontrib><creatorcontrib>Hasegawa, Naoki</creatorcontrib><creatorcontrib>Nakamura, Morio</creatorcontrib><title>Nafamostat Mesylate Monotherapy in Patients with Moderate COVID-19: a Single-Center, Retrospective Study</title><title>Japanese Journal of Infectious Diseases</title><addtitle>Jpn J Infect Dis</addtitle><description>Coronavirus disease (COVID-19) has spread dramatically worldwide. Nafamostat mesylate inhibits intracellular entry of the novel severe acute respiratory syndrome coronavirus 2 and is believed to have therapeutic potential for treating patients with COVID-19. In this study, patients with moderate COVID-19 who were admitted to our hospital were retrospectively analyzed. Thirty-one patients received monotherapy with nafamostat mesylate, and 33 patients were treated conservatively. Nafamostat mesylate was administered with continuous intravenous infusion for an average of 4.5 days. Compared with the conservative treatment, nafamostat mesylate did not improve outcomes or laboratory data 5 days after admission. In addition, no significant differences in laboratory data 5 days after admission and outcomes in high-risk patients were observed. The incidence of hyperkalemia was significantly higher in the nafamostat mesylate group; however, none of the patients required additional treatment. In conclusion, monotherapy with nafamostat mesylate did not improve clinical outcomes in patients with moderate COVID-19. This study did not examine the therapeutic potential of combining nafamostat mesylate with other antiviral agents, and further investigation is required. Because of the high incidence of hyperkalemia, regular laboratory monitoring is required during the use of nafamostat mesylate.</description><subject>Antiviral agents</subject><subject>coronavirus disease</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Health services</subject><subject>Hyperkalemia</subject><subject>Intravenous administration</subject><subject>Intravenous infusion</subject><subject>Laboratories</subject><subject>nafamostat mesylate</subject><subject>Patients</subject><subject>Risk groups</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>single-center study</subject><subject>Viral diseases</subject><issn>1344-6304</issn><issn>1884-2836</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNpdkV1v0zAUhi3ExD7gFyAhS9xwsRR_x-YOdcA6bQwx4NZynJM1JU2K7YDy7-eupRLc2JbOc14dnwehl5TMSq3522n4Cf3s6mpxMWOE0Zky5gk6oVqLgmmunuY3F6JQnIhjdBrjihAmJSXP0DGXwlDGxAlafnaNWw8xuYRvIE6dS4Bvhn5ISwhuM-G2x19caqFPEf9p0zIX61zJ1Pz2x-KioOYddviu7e87KOYZg3COv0IKQ9yAT-1vwHdprKfn6KhxXYQX-_sMff_44dv8sri-_bSYv78uvBDGFN5VFAgBCabmgkLtTV2rWleaUmaAg2ukKssGSiM5lBUoSQQVRitTUW08P0NvdrmbMPwaISa7bqOHrnM9DGO0TEmthGBMZfT1f-hqGEOfp7OsZIRSTgXJFN9RPn8pBmjsJrRrFyZLid2KsI8i7FaE3YqwWUTuerXPHqs11Ieev5vPwGIHrPLu7-EAuJBa38E-tJRWbo9_wg-MX7pgoecP5F6fHg</recordid><startdate>20220930</startdate><enddate>20220930</enddate><creator>Soma, Tomomi</creator><creator>Fujii, Kentaro</creator><creator>Yoshifuji, Ayumi</creator><creator>Maruki, Taketomo</creator><creator>Itoh, Kazuto</creator><creator>Taniyama, Daisuke</creator><creator>Kikuchi, Takahide</creator><creator>Hasegawa, Naoki</creator><creator>Nakamura, Morio</creator><general>National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee</general><general>Japan Science and Technology Agency</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T5</scope><scope>7T7</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20220930</creationdate><title>Nafamostat Mesylate Monotherapy in Patients with Moderate COVID-19: a Single-Center, Retrospective Study</title><author>Soma, Tomomi ; Fujii, Kentaro ; Yoshifuji, Ayumi ; Maruki, Taketomo ; Itoh, Kazuto ; Taniyama, Daisuke ; Kikuchi, Takahide ; Hasegawa, Naoki ; Nakamura, Morio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4499-cab1e00e5e9d341edc9dd6d8b81129e3eaf5677fe7953e7be6504149869b189c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antiviral agents</topic><topic>coronavirus disease</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Health services</topic><topic>Hyperkalemia</topic><topic>Intravenous administration</topic><topic>Intravenous infusion</topic><topic>Laboratories</topic><topic>nafamostat mesylate</topic><topic>Patients</topic><topic>Risk groups</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>single-center study</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soma, Tomomi</creatorcontrib><creatorcontrib>Fujii, Kentaro</creatorcontrib><creatorcontrib>Yoshifuji, Ayumi</creatorcontrib><creatorcontrib>Maruki, Taketomo</creatorcontrib><creatorcontrib>Itoh, Kazuto</creatorcontrib><creatorcontrib>Taniyama, Daisuke</creatorcontrib><creatorcontrib>Kikuchi, Takahide</creatorcontrib><creatorcontrib>Hasegawa, Naoki</creatorcontrib><creatorcontrib>Nakamura, Morio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese Journal of Infectious Diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soma, Tomomi</au><au>Fujii, Kentaro</au><au>Yoshifuji, Ayumi</au><au>Maruki, Taketomo</au><au>Itoh, Kazuto</au><au>Taniyama, Daisuke</au><au>Kikuchi, Takahide</au><au>Hasegawa, Naoki</au><au>Nakamura, Morio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nafamostat Mesylate Monotherapy in Patients with Moderate COVID-19: a Single-Center, Retrospective Study</atitle><jtitle>Japanese Journal of Infectious Diseases</jtitle><addtitle>Jpn J Infect Dis</addtitle><date>2022-09-30</date><risdate>2022</risdate><volume>75</volume><issue>5</issue><spage>484</spage><epage>489</epage><pages>484-489</pages><artnum>JJID.2021.699</artnum><issn>1344-6304</issn><eissn>1884-2836</eissn><abstract>Coronavirus disease (COVID-19) has spread dramatically worldwide. Nafamostat mesylate inhibits intracellular entry of the novel severe acute respiratory syndrome coronavirus 2 and is believed to have therapeutic potential for treating patients with COVID-19. In this study, patients with moderate COVID-19 who were admitted to our hospital were retrospectively analyzed. Thirty-one patients received monotherapy with nafamostat mesylate, and 33 patients were treated conservatively. Nafamostat mesylate was administered with continuous intravenous infusion for an average of 4.5 days. Compared with the conservative treatment, nafamostat mesylate did not improve outcomes or laboratory data 5 days after admission. In addition, no significant differences in laboratory data 5 days after admission and outcomes in high-risk patients were observed. The incidence of hyperkalemia was significantly higher in the nafamostat mesylate group; however, none of the patients required additional treatment. In conclusion, monotherapy with nafamostat mesylate did not improve clinical outcomes in patients with moderate COVID-19. This study did not examine the therapeutic potential of combining nafamostat mesylate with other antiviral agents, and further investigation is required. Because of the high incidence of hyperkalemia, regular laboratory monitoring is required during the use of nafamostat mesylate.</abstract><cop>Japan</cop><pub>National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee</pub><pmid>35491224</pmid><doi>10.7883/yoken.JJID.2021.699</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1344-6304 |
| ispartof | Japanese Journal of Infectious Diseases, 2022/09/30, Vol.75(5), pp.484-489 |
| issn | 1344-6304 1884-2836 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2658644226 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese |
| subjects | Antiviral agents coronavirus disease Coronaviruses COVID-19 Health services Hyperkalemia Intravenous administration Intravenous infusion Laboratories nafamostat mesylate Patients Risk groups SARS-CoV-2 Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 single-center study Viral diseases |
| title | Nafamostat Mesylate Monotherapy in Patients with Moderate COVID-19: a Single-Center, Retrospective Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T15%3A51%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nafamostat%20Mesylate%20Monotherapy%20in%20Patients%20with%20Moderate%20COVID-19:%20a%20Single-Center,%20Retrospective%20Study&rft.jtitle=Japanese%20Journal%20of%20Infectious%20Diseases&rft.au=Soma,%20Tomomi&rft.date=2022-09-30&rft.volume=75&rft.issue=5&rft.spage=484&rft.epage=489&rft.pages=484-489&rft.artnum=JJID.2021.699&rft.issn=1344-6304&rft.eissn=1884-2836&rft_id=info:doi/10.7883/yoken.JJID.2021.699&rft_dat=%3Cproquest_cross%3E2720113140%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2720113140&rft_id=info:pmid/35491224&rfr_iscdi=true |